Skip to main content

Finance & News Intelligence

AI-powered analysis of financial markets, economics, world news, and technology. Data-driven insights you can trust.

Stocks

47 US equities

Updated February 24, 2026

Treasuries

US bonds

Updated February 21, 2026

Brokers

12 US brokerages

Gilts

UK bonds

Updated February 23, 2026

Gold

Commodities

Updated February 21, 2026

Articles

Finance & news

Portfolio Updates

IBMFebruary 24, 2026

IBM Analysis: Anthropic's COBOL Bombshell Erases $30 Billion — Opportunity or the Beginning of the End?

CRMFebruary 23, 2026

CRM Analysis: Salesforce Hits 52-Week Low Ahead of Earnings — Is the AI Disruption Sell-Off Overdone?

AAPLFebruary 23, 2026

AAPL Analysis: The 2.5 Billion Device Ecosystem Powers a $3.9 Trillion Juggernaut — But Is the Premium Justified?

MRKFebruary 22, 2026

MRK Analysis: Merck's Keytruda Patent Cliff Looms — But a $305 Billion Pipeline Bet Could Rewrite the Bear Case

ABBVFebruary 22, 2026

ABBV Analysis: AbbVie's Post-Humira Reinvention — How Rinvoq and Skyrizi Are Rewriting the Growth Story

HDFebruary 22, 2026

HD Analysis: Home Depot's $380 Billion Bet on the Pro — Why the Housing Slowdown Hasn't Broken America's Largest Home Improvement Retailer

GiltsFebruary 23, 2026

Gilts: A Cautious Thaw as the BoE Navigates Between Persistence and Weakness

GoldFebruary 21, 2026

Gold: Real Yields, Inflation, and the Case for a 5-10% Portfolio Allocation at $5,000

TreasuriesFebruary 21, 2026

Treasuries: The Yield Curve Has Normalized After Two Years of Inversion — What the 60-Basis-Point Spread Signals for Bonds, the Fed, and Your Portfolio

Latest Analysis

View All
FinanceNovo NordiskOzempicWegovy

Market Watch: Novo Nordisk Slashes Ozempic and Wegovy Prices by Up to 50% as CagriSema Setback Deepens Competitive Crisis

Novo Nordisk dropped a bombshell on Tuesday, announcing it will slash the U.S. list prices of its blockbuster weight-loss and diabetes drugs — Wegovy, Ozempic, and Rybelsus — by up to 50% starting January 1, 2027. All three treatments will carry a new list price of $675 per month, down from approximately $1,350 for Wegovy and $1,027 for the diabetes drugs. The move is specifically designed to relieve the cost burden on insured patients with high-deductible health plans or coinsurance benefit structures. The announcement lands at perhaps the worst possible moment for the Danish pharmaceutical giant. Just one day earlier, shares cratered 16% after Novo's next-generation obesity drug CagriSema failed to demonstrate non-inferiority against Eli Lilly's Zepbound in the pivotal REDEFINE-4 phase III trial. The double blow has sent NVO shares tumbling to $38.58 — a new 52-week low — erasing more than half its market capitalization from last year's peak of $93.80. The stock is now down nearly 59% from its highs, and trading at its lowest P/E ratio in years at just 10.5x earnings. For investors, the twin developments crystallize a question that has been building for months: Is Novo Nordisk ceding the GLP-1 weight-loss throne to Eli Lilly, or is this a generational buying opportunity for one of pharma's most profitable franchises?

February 24, 2026Read Analysis
NewsAnthropicPentagonartificial intelligence

Developing: Pentagon and Anthropic Clash Over Military AI Guardrails as Defense Secretary Hegseth Meets CEO Amodei

Defense Secretary Pete Hegseth met Tuesday morning with Anthropic CEO Dario Amodei at the Pentagon in a high-stakes showdown over whether the artificial intelligence company will be permitted to maintain its own ethical guardrails on how the U.S. military uses its technology. The meeting comes after weeks of escalating tension between the Department of Defense — now rebranded as the Department of War — and the AI startup, which holds a contract worth up to $200 million and is the only frontier AI company to have deployed models on classified military networks. At the heart of the dispute is a fundamental question that extends far beyond any single contract: Who gets to decide the ethical boundaries of AI in warfare — the companies that build the technology, or the government that wields it? Anthropic has insisted its Claude AI systems must not be used for fully autonomous weapons or domestic surveillance of American citizens. The Pentagon has demanded the right to use all AI tools for "any lawful use" without company-imposed restrictions. The confrontation arrives at a moment when Anthropic is simultaneously shaking multiple industries. In just the past week, the company's new AI tools have triggered massive sell-offs in cybersecurity and legacy software stocks, while its accusations of intellectual property theft by Chinese AI firms have added a geopolitical dimension to its already outsized influence. With a valuation of $380 billion following a $30 billion funding round earlier this month, Anthropic finds itself at the center of nearly every major AI debate in 2026.

February 24, 2026Read Analysis
FinancePEG ratioprice-earnings-to-growthstock valuation

Deep Dive: What Is the PEG Ratio — How It Combines Price, Earnings, and Growth Into One Valuation Metric

The price-to-earnings (P/E) ratio is the most widely cited valuation metric in investing — but used in isolation, it can be deeply misleading. A stock trading at 47 times earnings looks expensive next to one at 23 times earnings. But what if the first company is growing earnings at 57% annually while the second is growing at 15%? Suddenly the picture inverts. That is exactly the problem the PEG ratio solves. The PEG ratio — short for price/earnings-to-growth — adjusts the P/E ratio by the company's earnings growth rate, giving investors a single number that accounts for both what they are paying and what they are getting in return. Developed by investor Peter Lynch and popularized in his 1989 book *One Up on Wall Street*, the PEG ratio remains one of the most practical tools for comparing growth stocks on a level playing field. With the Federal Reserve cutting rates from 4.33% in August 2025 to 3.64% in January 2026, growth stocks have surged — and so have their P/E ratios. In this environment, PEG becomes especially valuable: it helps investors distinguish between stocks that are genuinely expensive and those that are simply priced for the growth they are delivering.

February 24, 2026Read Analysis
Financemonopoly investingantitrust regulationeconomic moat

Deep Dive: Are Monopolies Always Bad — How Market Dominance Affects Investors and What It Means for Your Portfolio

When economists discuss monopolies, the conversation typically centers on consumer harm — higher prices, less innovation, and reduced choice. But for investors, market dominance tells a very different story. Companies that control their markets often deliver the most consistent returns, the widest profit margins, and the deepest competitive moats in the entire stock market. The five largest U.S. technology companies — Apple ($3.91 trillion market cap), Alphabet ($3.77 trillion), Microsoft ($2.85 trillion), Amazon ($2.20 trillion), and Meta ($1.61 trillion) — collectively represent over $14 trillion in market value as of February 2026. Each faces ongoing antitrust scrutiny from regulators worldwide, yet each continues to generate extraordinary returns for shareholders. This tension between regulatory risk and investment returns is the central question every investor in dominant companies must navigate. Understanding how monopolistic power creates value — and when regulatory intervention can destroy it — is essential for building a resilient portfolio. This guide examines market dominance through the investor's lens: the competitive advantages it creates, the risks it introduces, and how to evaluate whether a dominant company's premium valuation is justified.

February 24, 2026Read Analysis
Financeprice-to-sales ratioP/S ratiostock valuation

Deep Dive: What Is the Price-to-Sales (P/S) Ratio — How to Calculate It and When It Matters Most for Investors

When Palantir Technologies trades at nearly 70 times its annual revenue while Walmart barely exceeds one times sales, the gap can seem absurd — until you understand what the price-to-sales ratio is actually measuring. The P/S ratio is one of the most intuitive valuation metrics in an investor's toolkit, and it becomes indispensable in exactly the situations where the more popular price-to-earnings ratio breaks down. With mega-cap growth stocks like NVIDIA commanding a P/S ratio above 24x ahead of its February 25 earnings report, and Salesforce trading at roughly 4x sales near its 52-week low, understanding how to interpret these numbers separates informed investors from those chasing headlines. The P/S ratio strips away the accounting complexity of earnings and asks a simpler question: how much are investors willing to pay for each dollar of revenue a company generates? This guide breaks down how to calculate the P/S ratio, what it reveals about different business models, where it works best, and — just as importantly — where it can lead you astray.

February 24, 2026Read Analysis
Financeconsumer confidence indexCCIconsumer sentiment

Deep Dive: What Is the Consumer Confidence Index — How It's Measured, Why It Moves Markets, and What It Means for Your Portfolio

Every month, a single number captures the collective mood of American consumers — and Wall Street pays close attention. The Consumer Confidence Index (CCI), published by The Conference Board, is one of the most closely watched economic indicators in the United States. When confidence rises, it signals that households are willing to spend, borrow, and invest. When it falls, it often foreshadows economic slowdowns, reduced corporate earnings, and market turbulence. For investors, the CCI is more than a sentiment gauge — it's a leading indicator with a track record of anticipating shifts in consumer spending, which accounts for roughly 70% of U.S. GDP. Understanding how the index works, what drives its movements, and how to interpret its signals can give you a meaningful edge in portfolio positioning. With consumer sentiment currently in flux — the University of Michigan's Consumer Sentiment Index read 56.4 in January 2026, well below its February 2025 level of 64.7 — the question of where consumers stand has rarely been more relevant.

February 23, 2026Read Analysis
Browse All Articles